|
|
SAVE
10% AS A CHI CONTACT* |
 |
Now
Available as Part of CHI's
Network of Approved
Reports |
 |
|
|

 |
NEW! Analysis of Oncology Deals: Trends in Deal Structures and Valuations
Pre-Order
before November 20 and SAVE an additional 10%
The report will contain:
-
Market data on therapy area – facts and figures
-
An analysis of deal making and trends to provide pointers to
what is likely to happen in the therapy area.
-
Who are the top players?
-
What impact has the credit crunch and emerging markets in deal
making in this therapy area?
-
Broad predictions of direction of the market with quotes from
leading industry people.
-
Which technologies are driving the deals and why are they
attractive
-
A reference section with case studies of handpicked deals with
SEC analysis where available
View the Table of Contents |
|
|
|
|

 |
NEW!
The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
The Definitive Industry Reference, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal.
"The report sets out to give the reader a full insight into determining valuation and royalties and the huge impact that these terms can have on deals and their ultimate survival."
Dr Fintan Walton,
CEO of PharmaVentures
The content has been formulated by leveraging over 15 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, and in response to valued feedback from our extensive market research. This report follows on from the publication of previous top selling reports on the topic of royalty rates.
- Clear guidance on the best methodologies to use when calculating Royalty Rates to assist with vital decision making
- Opinions and advice from leading industry deal makers on how to calculate Royalty Rates
- Contextual information – The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?”
- More case studies – PharmaVentures highlights the issues and pitfalls so that you can avoid them
Click
here to view the full table of contents
|
|
|
|
|

 |
NEW!
Effective Deal Making in Drug Delivery
"Looming
patent expiry a major force in driving valuation"Drugs with annual sales totaling over US$86 B in 2007 are due to
go off patent by 2012. Therefore, the application of novel drug
delivery technologies to such existing therapeutics is an
attractive means of prolonging the commercial viability of
marketed drugs.
Technologies are more difficult to value than products in
clinical development because the technical risks or success
rates are less well documented, and costs and timescales are
less predictable.
It is very important to benchmark when valuing technologies and
to have a thorough understanding of the risks and rewards.
This new PharmaDeals® Report, covers the range of strategies and
offerings available to the deal maker, and is vital for
understanding growth and survival in volatile markets.
Click
here to view the full table of contents
|
|
|
|
|

 |
NEW!
Trends in Pharmaceutical Deal Making: An Analysis of Valuations, Deal Structures and Deal Types
This report
is a must-have report for all involved in business development,
marketing or competitive intelligence in understanding what lies
behind such deals and how they come about.
In deal
making, it can be hard to pick the optimum deal type for your
situation. Even the most accomplished deal maker is unlikely to
have been involved in each and every type of deal.
This
indispensable report answers numerous key questions including:
-
What is
the rationale for different deal structures?
-
What is
the most relevant deal type to use in a particular
situation?
-
What are the
key issues that must be considered for each deal type?
-
How do I
value these deals?
-
What do
these deals look like in real life?
-
What is the
impact of the economic downturn on deals?
The report
analyses each type of deal in detail and, in addition, is
supported by extensive analysis and case studies of real life
examples from PharmaDeals® v2 Agreements and
PharmaDeals Review.
Click
here to view the full table of contents
|
|
|
|
|

 |
NEW!
Guide to Valuation of Pharmaceutical Licensing Deals
Building on an established reputation in the area of deal
negotiation and valuation, PharmaVentures is pleased to announce
the release of their revised, best-selling Industry Standard
Report.
This important Report takes into account all recent developments
and focuses on the issues of most concern to business
development and licensing professionals within the large
pharmaceutical, biotechnology and academic network. It fully
addresses financial modeling and provides detailed valuation
examples. Its content has been formulated and thoroughly tested.
The Report will:
-
Provide a thorough understanding of robust valuation
methodologies
-
Enable more rigorous economic portfolio analysis
-
Offer greater transparency in portfolio analysis
-
Assist the formulation of attractive deal structures
-
Permit accurate comparison of alternative deals
-
Highlight the value creation process
-
Minimise risk in future deals
It is an essential reference source for all those aiming to
maximise deal values and minimise risk.
Click
here to view the full table of contents
|
|
|
|
|


|
Competition Law and Intellectual Property Strategy in the
Pharmaceuticals Sector
The report, written by Bird
& Bird's leading lawyers, sets out the essential
issues concerning the intellectual property regime and the
application of competition law in the pharmaceuticals sector,
and the sector-specific regulatory provisions affecting
competition.
The resulting case law both at
EU level and at national level implementing the EU rules on
competition and the related regulatory developments are central
to the strategic decisions of pharmaceuticals suppliers.
Looking at leading
cases within the pharmaceuticals sector, involving companies
such as GlaxoSmithKline, Boehringer Ingelheim, Bayer,
Organon, Johnson & Johnson, AstraZeneca, Napp
Pharmaceuticals and Genzyme to
illustrate the key points, the report examines essential issues,
including the following:
- How legislation and case law
has set out limits in various areas on the extents to which
intellectual property owners can enforce their patents
- Parallel importation under
the EC rules on free circulation of goods and the EC
competition rules, agreements and conduct restricting
parallel imports and exports
- Meaning of an agreement
under the EC competition rules
- Conduct of dominant
suppliers with regard to pricing issues
- Commission guidelines on the
application of competition rules to R&D collaboration
agreements
- Effect of regulation on
technology licensing, marketing and distribution agreements
UK and EC competition
authorities' commitment to private enforcement of the
competition rules to combat cartels
Click
here to view the full table of contents
|
|
|
|
|


|
Pricing and Reimbursement: Risk and Opportunity in Pharmaceutical Deal Making
The report
covers those essential market changing initiatives which make
tomorrow’s drug market different from today’s. Successful
deal making has accurate valuation at its heart. Anything that
impacts a drugs ability to achieve in the future a fair and
profitable market price impacts its value today. The current
market is more challenging than ever before. Payer-driven price
negotiation for reimbursement, and cost-containment programmes
to control prescribing both challenge the traditional pricing
model the industry has used to generate valuable R&D
resource to further the search for innovation and better disease
control.
Click
here to view the executive summary
|
|
|
|
|


|
Spotlight Report Series
PharmaVentures publishes a series of reports dedicated to assisting companies in
business development and deal making in the pharmaceutical & healthcare sectors.
Published reports include:
PharmaDeals® Deal Making Spotlight Reports
Deal Making Spotlight on Pfizer
Deal Making Spotlight on sanofi-aventis
Deal Making Spotlight on GlaxoSmithKline
Deal Making Spotlight on Johnson & Johnson
Deal Making Spotlight on Novartis
Detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.
Click
here to view the table of contents |
|
|
|
|

|
Spotlight on Influenza - Separating Fact from Fiction in the Battle Against Influenza
Focusing on the hot topic of influenza, this report offers a topical insight into both the flu virus and the methods being employed to tackle it. From an investigative angle, the report specifically explores the pharmaceutical industry's R&D endeavours in combating the virus, affording a comprehensive insight into key players in the arena. Main areas of focus covered by the report include:
- The virus and its history
- Key industry insight
- An analysis of the market
- Summary of influenza-related deals
View
the table of contents |
|
|
|
|

|
Strategies and Tactics for Successful Partnering
This report
provides in-depth information and practical advice relating to
the partnering process. Based on PharmaVentures' experiences of
working with pharmaceutical and biotechnology companies
worldwide, this comprehensive report provides an insight into
the challenges and rewards of the partnering process. The report
includes quotations documenting industry-partnering experiences,
and is a must read for anyone needing to complete & manage
deals.
Click
here to view the executive summary |
|
|
|
* Discount does not
apply to reports already purchased
|